Further inquiry into treating hepatitis C with recombinant interferon alpha.
Puoti
C
C
Fuiano
B
B
Annovazzi
G
G
Pannullo
A
A
Patane
F
F
D015415:Biomarkers / Q000097:blood; D002908:Chronic Disease; D004351:Drug Resistance; D006509:Hepatitis B / Q000150:complications* / Q000276:immunology; D006510:Hepatitis B Antibodies / Q000032:analysis / Q000276:immunology; D006515:Hepatitis B virus / Q000276:immunology; D006526:Hepatitis C / Q000150:complications / Q000628:therapy*; D006521:Hepatitis, Chronic / Q000209:etiology / Q000628:therapy*; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use*; D008103:Liver Cirrhosis / Q000150:complications*; D011379:Prognosis; D011994:Recombinant Proteins; D012008:Recurrence
D015415:Biomarkers; D006510:Hepatitis B Antibodies; D007370:Interferon Type I; D011994:Recombinant Proteins